A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE)

Publication Date

6-1-2024

Presented At:

American Society of Clinical Oncology (ASCO) Annual Meeting

This document is currently not available here.

Share

COinS